

CITATION REPORT

List of articles citing

Companion and Complementary Diagnostics-Focus on PD-L1 Expression Assays for PD-1/PD-L1 Checkpoint Inhibitors in Non-Small Cell Lung Cancer

DOI: 10.1097/ftd.00000000000000460

Therapeutic Drug Monitoring, 2018, 40, 9-16.

Source: <https://exaly.com/paper-pdf/69553905/citation-report.pdf>

Version: 2024-04-25

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
77	The ESMO Precision Medicine Glossary. <i>Annals of Oncology</i> , 2018 , 29, 781-782	10.3	0
76	Clinical and Regulatory Aspects of Companion Diagnostic Development in Oncology. <i>Clinical Pharmacology and Therapeutics</i> , 2018 , 103, 999-1008	6.1	19
75	Next-Generation Novel Noninvasive Cancer Molecular Diagnostics Platforms Beyond Tissues. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2018 , 38, 964-977	7.1	10
74	Novel Quantitative Imaging for Predicting Response to Therapy: Techniques and Clinical Applications. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2018 , 38, 1008-1018	7.1	34
73	Tumor mutational burden in non-small cell lung cancer-the pathologist's point of view. <i>Translational Lung Cancer Research</i> , 2018 , 7, 716-721	4.4	8
72	Companion and complementary diagnostics for first-line immune checkpoint inhibitor treatment in non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2018 , 7, S95-S99	4.4	7
71	The importance of PD-L1 diagnostic assay harmonization for the selection of lung cancer immunotherapy. <i>Journal of Thoracic Disease</i> , 2018 , 10, S4096-S4100	2.6	3
70	Cytokines, Chemokines, and Other Biomarkers of Response for Checkpoint Inhibitor Therapy in Skin Cancer. <i>Frontiers in Medicine</i> , 2018 , 5, 351	4.9	37
69	The usefulness of various cytologic specimen preparations for PD-L1 immunostaining in non-small cell lung carcinoma. <i>Journal of the American Society of Cytopathology</i> , 2018 , 7, 324-332	2.4	8
68	Anti-PD-1/PD-L1 Therapy for Non-Small-Cell Lung Cancer: Toward Personalized Medicine and Combination Strategies. <i>Journal of Immunology Research</i> , 2018 , 2018, 6984948	4.5	100
67	PD-L2 amplification and durable disease stabilization in patient with urothelial carcinoma receiving pembrolizumab. <i>Oncolmmunology</i> , 2018 , 7, e1460298	7.2	10
66	Impaired dendritic cell functions in lung cancer: a review of recent advances and future perspectives. <i>Cancer Communications</i> , 2019 , 39, 43	9.4	29
65	Accurate expression of PD-L1/L2 in lung adenocarcinoma cells: A retrospective study by double immunohistochemistry. <i>Cancer Science</i> , 2019 , 110, 2711-2721	6.9	17
64	Programmed death ligand-1/programmed death-1 inhibition therapy and programmed death ligand-1 expression in urothelial bladder carcinoma. <i>Chronic Diseases and Translational Medicine</i> , 2019 , 5, 170-177	3.9	2
63	Road map to best practices. 2019 , 241-273		0
62	Role of the dynamic tumor microenvironment in controversies regarding immune checkpoint inhibitors for the treatment of non-small cell lung cancer (NSCLC) with EGFR mutations. <i>Molecular Cancer</i> , 2019 , 18, 139	42.1	78
61	Implementing TMB measurement in clinical practice: considerations on assay requirements. <i>ESMO Open</i> , 2019 , 4, e000442	6	136

60	Expression of programmed death ligand (PD-L1) in different tumors. Comparison of several current available antibody clones and antibody profiling. <i>Annals of Diagnostic Pathology</i> , 2019 , 41, 24-37	2.2	25
59	The Drug-Diagnostic Codevelopment Model. 2019 , 11-25		
58	Companion and Complementary Diagnostics by Mass Spectrometry. 2019 , 187-200		
57	Regulatory Requirements for Companion Diagnostics and Drug Diagnostic Codevelopment in the United States. 2019 , 307-318		1
56	Companion Diagnostics and Biomarker Tests in the European Medicines Agency Assessment of Medicinal Products. 2019 , 319-333		3
55	Assessment of PD-L1 mRNA and protein expression in non-small cell lung cancer, head and neck squamous cell carcinoma and urothelial carcinoma tissue specimens using RNAScope and immunohistochemistry. <i>PLoS ONE</i> , 2019 , 14, e0215393	3.7	9
54	Immunotherapy in colorectal cancer: rationale, challenges and potential. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2019 , 16, 361-375	24.2	427
53	Immunotherapy in Non-Small Cell Lung Cancer: Facts and Hopes. <i>Clinical Cancer Research</i> , 2019 , 25, 4592-4602	24.1	241
52	Clinicopathological values of PD-L1 expression in HER2-positive breast cancer. <i>Scientific Reports</i> , 2019 , 9, 16662	4.9	21
51	Reliability of PD-L1 assays using small tissue samples compared with surgical specimens. <i>Medicine (United States)</i> , 2019 , 98, e14972	1.8	10
50	Fit-For-Purpose PD-L1 Biomarker Testing For Patient Selection in Immuno-Oncology: Guidelines For Clinical Laboratories From the Canadian Association of Pathologists-Association Canadienne Des Pathologistes (CAP-ACP). <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2019 , 27, 699-714	1.9	23
49	Fine-needle aspiration cytology of non-small cell lung carcinoma: A paradigm shift. <i>Diagnostic Cytopathology</i> , 2019 , 47, 351-358	1.4	3
48	Role of systemic inflammatory response markers in urological malignancy. <i>International Journal of Urology</i> , 2019 , 26, 31-47	2.3	26
47	Site-agnostic biomarker-guided oncology drug development. <i>Expert Review of Molecular Diagnostics</i> , 2020 , 20, 583-592	3.8	3
46	Emerging Blood-Based Biomarkers for Predicting Response to Checkpoint Immunotherapy in Non-Small-Cell Lung Cancer. <i>Frontiers in Immunology</i> , 2020 , 11, 603157	8.4	10
45	Biomarkers or factors for predicting the efficacy and adverse effects of immune checkpoint inhibitors in lung cancer: achievements and prospective. <i>Chinese Medical Journal</i> , 2020 , 133, 2466-2475	2.9	0
44	VEGF-A Is Associated With the Degree of TILs and PD-L1 Expression in Primary Breast Cancer. <i>In Vivo</i> , 2020 , 34, 2641-2646	2.3	2
43	CD44, a marker of cancer stem cells, is positively correlated with PD-L1 expression and immune cells infiltration in lung adenocarcinoma. <i>Cancer Cell International</i> , 2020 , 20, 583	6.4	11

42	High tumor mutation burden is associated with DNA damage repair gene mutation in breast carcinomas. <i>Diagnostic Pathology</i> , 2020 , 15, 50	3	15
41	Improving the Diagnostic Accuracy of the PD-L1 Test with Image Analysis and Multiplex Hybridization. <i>Cancers</i> , 2020 , 12,	6.6	20
40	PD-L1 expression and efficacy of pembrolizumab as monotherapy in NSCLC. <i>Chinese Clinical Oncology</i> , 2020 , 9, 60	2.3	3
39	Update on molecular companion diagnostics - a future in personalized medicine beyond Sanger sequencing. <i>Expert Review of Molecular Diagnostics</i> , 2020 , 20, 637-644	3.8	4
38	Regulatory perspectives on next-generation sequencing and complementary diagnostics in Japan. <i>Expert Review of Molecular Diagnostics</i> , 2020 , 20, 601-610	3.8	1
37	Immunotherapy with immune checkpoint inhibitors in colorectal cancer: what is the future beyond deficient mismatch-repair tumours?. <i>Gastroenterology Report</i> , 2020 , 8, 11-24	3.3	43
36	Predictive effect of PD-L1 expression for immune checkpoint inhibitor (PD-1/PD-L1 inhibitors) treatment for non-small cell lung cancer: A meta-analysis. <i>International Immunopharmacology</i> , 2020 , 80, 106214	5.8	18
35	Expanding the Scope of Immunotherapy in Colorectal Cancer: Current Clinical Approaches and Future Directions. <i>BioMed Research International</i> , 2020 , 2020, 9037217	3	26
34	FDG uptake reflects breast cancer immunological features: the PD-L1 expression and degree of TILs in primary breast cancer. <i>Breast Cancer Research and Treatment</i> , 2020 , 181, 331-338	4.4	13
33	Effectiveness of PD-1/PD-L1 inhibitors in the treatment of lung cancer: Brightness and challenge. <i>Science China Life Sciences</i> , 2020 , 63, 1499-1514	8.5	12
32	In Vivo Evaluation and Dosimetry Estimate for a High Affinity Affibody PET Tracer Targeting PD-L1. <i>Molecular Imaging and Biology</i> , 2021 , 23, 241-249	3.8	5
31	Reviving up dendritic cells can run cancer immune wheel in non-small cell lung cancer: a prospective two-arm study. <i>Cancer Immunology, Immunotherapy</i> , 2021 , 70, 733-742	7.4	3
30	Checkpoint inhibitors: Interface of cancer and autoimmunity: Opportunity for second level precision medicine. 2021 , 109-134		
29	Blocking IL-17A enhances tumor response to anti-PD-1 immunotherapy in microsatellite stable colorectal cancer. 2021 , 9,		21
28	Precision Medicine. 2021 , 115-120		
27	Harnessing non-destructive 3D pathology. <i>Nature Biomedical Engineering</i> , 2021 , 5, 203-218	19	12
26	An update on companion and complementary diagnostic assays for PD-1/PD-L1 checkpoint inhibitors in NSCLC. <i>Expert Review of Molecular Diagnostics</i> , 2021 , 21, 445-454	3.8	0
25	Plasma Proteomic Analysis in Non-Small Cell Lung Cancer Patients Treated with PD-1/PD-L1 Blockade. <i>Cancers</i> , 2021 , 13,	6.6	4

24	Translational precision medicine: an industry perspective. <i>Journal of Translational Medicine</i> , 2021 , 19, 245	8.5	12
23	Prognostic prospect of soluble programmed cell death ligand-1 in cancer management. <i>Acta Biochimica Et Biophysica Sinica</i> , 2021 , 53, 961-978	2.8	2
22	Safety and Efficacy of Anti-PD-1/PD-L1 Inhibitors Compared With Docetaxel for NSCLC: A Systematic Review and Meta-Analysis. <i>Frontiers in Pharmacology</i> , 2021 , 12, 699892	5.6	3
21	The Pandora's box of novel technologies that may revolutionize lung cancer. <i>Lung Cancer</i> , 2021 , 159, 34-41	5.9	3
20	Clinical Efficacy and Future Prospects of Immunotherapy in Lung Cancer. <i>Life</i> , 2021 , 11,	3	2
19	Modeling Challenges in Cost-Effectiveness Analysis of First-Line Immuno-Oncology Therapies in Non-small Cell Lung Cancer: A Systematic Literature Review. <i>Pharmacoeconomics</i> , 2021 , 1	4.4	
18	Spatial mapping of the tumor immune microenvironment. 2022 , 293-329		
17	Spatiotemporal Changes in Checkpoint Molecule Expression. <i>Advances in Experimental Medicine and Biology</i> , 2020 , 1248, 167-200	3.6	3
16	The Immunohistochemical Expression of Programmed Death Ligand 1 (PD-L1) Is Affected by Sample Overfixation. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2021 , 29, 76-81	1.9	3
15	A paradigm shift in biomarker guided oncology drug development. <i>Annals of Translational Medicine</i> , 2019 , 7, 148	3.2	18
14	Are radiomics ready for clinical prime-time in PET/CT imaging?. <i>Quarterly Journal of Nuclear Medicine and Molecular Imaging</i> , 2019 , 63, 347-354	1.4	1
13	Expression of PD-L1 for predicting response to immune checkpoint inhibitors in metastatic urothelial carcinoma: a systematic review and meta-analysis. <i>Current Oncology</i> , 2020 , 27, e656-e663	2.8	1
12	The daily practice reality of PD-L1 (CD274) evaluation in non-small cell lung cancer: A retrospective study. <i>Oncology Letters</i> , 2020 , 19, 3400-3410	2.6	5
11	Status of Biologic Drugs in Modern Therapeutics-Targeted Therapies vs. Small Molecule Drugs. 2020 , 31-46		
10	[Study Progression on Non-small Cell Lung Cancer with EGFR Mutation ?Treated by Immune Checkpoint Inhibitors]. <i>Chinese Journal of Lung Cancer</i> , 2018 , 21, 641-648	0.6	
9	Acute Phase Proteins as Early Predictors for Immunotherapy Response in Advanced NSCLC: An Explorative Study.. <i>Frontiers in Oncology</i> , 2022 , 12, 772076	5.3	0
8	Landscape of Immunotherapy Options for Colorectal Cancer: Current Knowledge and Future Perspectives beyond Immune Checkpoint Blockade.. <i>Life</i> , 2022 , 12,	3	3
7	Identification of a novel immune signature for optimizing prognosis and treatment prediction in colorectal cancer.. <i>Aging</i> , 2021 , 13, 25518-25549	5.6	0

6	The "digital biopsy" in non-small cell lung cancer (NSCLC): a pilot study to predict the PD-L1 status from radiomics features of [18F]FDG PET/CT.. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022 , 1	8.8	1
5	Immune cell infiltration pattern in non-small cell lung cancer PDX models is a model immanent feature and correlates with a distinct molecular and phenotypic make-up.. 2022 , 10,		0
4	Network meta-analysis of immune-oncology monotherapy as first-line treatment for advanced non-small-cell lung cancer in patients with PD-L1 expression ?50%. <i>Therapeutic Advances in Medical Oncology</i> , 2022 , 14, 175883592211050	5.4	0
3	Trends in real-world biomarker testing and overall survival in US patients with advanced non-small-cell lung cancer.		0
2	Neoadjuvant immunotherapy for colorectal cancer: Right regimens, right patients, right directions?. 14,		0
1	APC mutation correlated with poor response of immunotherapy in colon cancer. 2023 , 23,		0